HS
BBOT

HighVista Strategies’s BridgeBio Oncology BBOT Stock Holding History

HighVista Strategies’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,187
Closed -$700K – 181
2026
Q1 		$700K Sell
78,187
-151,076
-66% -$1.62M 0.19% 135
2025
Q4 		$2.87M Buy
+229,263
New +$2.78M 0.74% 46

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HighVista Strategies's BBOT Position: Q2 2026 in Review

HighVista Strategies sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 78,187 shares — an estimated $700K sold.

HighVista Strategies first reported a position in BBOT in Q4 2025 and held it in 2 quarters. The position peaked at $2.87M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • HighVista Strategies reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • HighVista Strategies sold 78,187 BridgeBio Oncology shares in Q2 2026, an estimated $700K.
  • HighVista Strategies first reported a position in BridgeBio Oncology in Q4 2025 and held it in 2 quarters.
  • HighVista Strategies's BridgeBio Oncology position peaked at $2.87M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.